Streetbeat News

Price Targets

SKYW

Evercore ISI Group analyst Duane Pfennigwerth maintains an In-Line rating on SkyWest (NASDAQ:SKYW) and raises the price target from $38 to $45.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 2:08 pm

BURL

TD Cowen analyst John Kernan maintains a Market Perform rating on Burlington Stores (NYSE:BURL) and lowers the price target from $185 to $181.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 2:07 pm

SAVE

Evercore ISI Group analyst Duane Pfenningwerth has maintained an In-Line rating on Spirit Airlines (NYSE:SAVE) but lowered the price target from $28 to $25.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 2:05 pm

LUV

Evercore ISI Group analyst Duane Pfenningwerth has maintained an 'Outperform' rating on Southwest Airlines (NYSE:LUV) but lowered the price target from $42 to $38.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 2:04 pm

ALGT

Evercore ISI Group analyst Duane Pfennigwerth maintains an In-Line rating on Allegiant Travel (NASDAQ:ALGT) and lowers the price target from $125 to $110.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 2:03 pm

COO

Mizuho analyst Anthony Petrone has reiterated a 'Buy' rating on Cooper Companies (NYSE:COO) and maintained a price target of $440.

Portfolio Pulse from richadhand@benzinga.com

August 28, 2023 | 2:02 pm

BA

TD Cowen analyst Cai Rumohr maintains an Outperform rating on Boeing (NYSE:BA) and raises the price target from $255 to $260.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 2:02 pm

AAL

Evercore ISI Group analyst Duane Pfennigwerth maintains an In-Line rating on American Airlines Group (NASDAQ:AAL) and lowers the price target from $19 to $17.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 2:00 pm

MMSI

Canaccord Genuity analyst William Plovanic maintains a 'Hold' rating on Merit Medical Systems (NASDAQ:MMSI) and lowers the price target from $86 to $70.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2023 | 1:59 pm

BBIO

Mizuho analyst Salim Syed has reiterated a 'Buy' rating on BridgeBio Pharma (NASDAQ:BBIO) and maintained a price target of $60.

Portfolio Pulse from richadhand@benzinga.com

August 28, 2023 | 1:58 pm